Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for ...
One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...
Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.
One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...
Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...
One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...